

Press release 2014-10-21

## **WntR updates information from the European Patent Office, which has granted patent on peptides related to Foxy-5**

**Correction of the headline:** the headline has been updated to clarify that the patent now granted does not relate to Foxy-5 but instead to Foxy-5 related peptide

WntResearch AB wishes to inform that -as the company announced in June, and commented further on in September - the European Patent Office has earlier informed the company that it intends to grant patent No. 1 888 628 concerning peptides related to the company's product Foxy-5. All remaining issues have now been dealt with, and accordingly the European Patent Office issued on 16 October 2014 a decision to grant the patent. At the same time, the European Patent Office informed the company that the patent will enter into force on 12 November 2014.

**For additional information please contact:**

Nils Brünner, VD  
E-post: [nbr@wntresearch.com](mailto:nbr@wntresearch.com)  
Telefon: + 45 2614 4708

**Om WntResearch**

WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase I – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.